Guohua Yu

机构：Weifang People's Hospital · ORCID：0009-0003-3441-0876

发表论文 76 篇 · 总被引 2215 次 · h-index 23

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 94)
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 52)
• SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. (2023 · Journal of Clinical Oncology · 被引 32)
• Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study (2024 · EBioMedicine · 被引 11)
• Hyaluronic acid-modified liposomes Co-encapsulating curcumin and mifepristone to enhance anti-breast cancer efficacy (2023 · Journal of Drug Delivery Science and Technology · 被引 11)
• Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer (2025 · Frontiers in Immunology · 被引 7)